We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a
Cardiol Therapeutics Initiated at Buy by Roth MKM
Cardiol Therapeutics Initiated at Buy by Roth MKM
Roth MKM Initiates Cardiol Therapeutics(CRDL.US) With Buy Rating, Announces Target Price $10
Roth MKM analyst Jason Wittes initiates coverage on $Cardiol Therapeutics(CRDL.US)$ with a buy rating, and sets the target price at $10.According to TipRanks data, the analyst has a success rate of 50
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 P.m. EDT
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $8
CCORF analyst Edward Nash maintains $Cardiol Therapeutics(CRDL.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 38.1% and a to
Stocks in Play: Cardiol Therapeutics Inc.
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
Sector Update: Health Care Stocks Softer Thursday Afternoon
Health care stocks fell Thursday afternoon with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.3%. The iShares Biotechnology ETF (IBB) fell 0.4%. I
Express News | Cardiol Therapeutics Shares Are Trading Lower. The Company Announced 8-week Clinical Data From Its Phase II Open-label MAvERIC-Pilot Study Investigating the Impact of CardiolRx Administered to Patients With Symptomatic Recurrent Pericarditis
Cardiol Slips After Mid-stage Data for Heart Disease Therapy
Cardiol Therapeutics Releases Phase II Data Showing CardiolRx Reduces Pericarditis Pain and Inflammation | TSX:CRDL, NASDAQ:CRDL
Cardiol Therapeutics Announces Positive Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx also shown to reduce inflammation in patients with elevated CRP89% of patients have
H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright analyst Vernon Bernardino maintains $Cardiol Therapeutics(CRDL.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate o
Cardiol Therapeutics Sets Annual Shareholders' Meeting
Cardiol Therapeutics Is Maintained at Buy by Canaccord Genuity
Cardiol Therapeutics Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $8
Cardiol Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/23/2024 257.14% Canaccord Genuity $6 → $8 Maintains Buy 05/14/2024 301.79% HC Wainwright & Co. → $9 Rei
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Raises Target Price to $8
CCORF analyst Edward Nash maintains $Cardiol Therapeutics(CRDL.US)$ with a buy rating, and adjusts the target price from $6 to $8.According to TipRanks data, the analyst has a success rate of 40.1% an
Express News | Cardiol Therapeutics Inc : Canaccord Genuity Raises Target Price to $8 From $6